Reddit 社区就 Prevnar 20 通过免疫原性桥接获 FDA 批准用于儿童的有效性展开辩论
Prevnar 20
Reddit r/DebateVaccines 用户讨论 Prevnar 20 于 2023-04-27 通过免疫原性桥接获 FDA 批准用于 6 周龄至 17 岁儿童，在维持与 Prevnar 13 等同抗体水平基础上多覆盖 7 种菌株；发帖者随后提出"25%有效率并不高"主张（⚠ 非 FDA 数据），评论要求其提供实际链接并质疑论述框架。
r/DebateVaccines 的 u/Illustrious_Ad704 解释 FDA 批准 Prevnar 20 用于婴幼儿/儿童时采用“免疫原性桥接”——证明与 Prevnar 13 产生等同抗体水平并多覆盖 7 种菌株——随后称“25% 有效率并不高”。评论质疑来源（u/CODMLoser 要求真实链接）及楼主框架。事实核验（✔）：Prevnar 20 于 2023-04-27 凭免疫原性桥接（对 Prevnar 13 非劣 IgG）获 FDA 批准用于 6 周–17 岁；“25% 有效率”是楼主争议性主张，非 FDA 数据。本帖为疫苗质疑讨论（⚠）。
核验 ✔ 已核验：Prevnar 20 于 2023-04-27 凭免疫原性桥接获批；⚠ 楼主“25%有效率”为争议性主张
发生了什么
A Reddit thread in r/DebateVaccines discusses FDA's 2023-04-27 approval of Prevnar 20 for children aged 6 weeks through 17 years, noting that the approval relied on immunogenicity bridging rather than direct efficacy endpoints. According to FDA documents, for each of the 13 serotypes shared with Prevnar 13, IgG geometric mean concentrations in the Prevnar 20 group were noninferior to those in the Prevnar 13 group, and Prevnar 20 adds 7 serotypes beyond the original 13 [1]. A Phase 3 study by Senders et al. (2024) confirmed this noninferiority after the third and fourth doses [2]. The original poster further claims "25% effectiveness," a figure that does not appear in the FDA or peer-reviewed materials provided and is flagged in the source as a controversial assertion.
为什么重要
The immunogenicity bridging pathway addresses a specific regulatory question: whether a higher-valent pneumococcal vaccine can be approved for children without repeating large endpoint-driven efficacy trials, by leveraging the established profile of Prevnar 13. For clinicians and public health decision-makers, this means protection against the 7 added serotypes rests on antibody-level equivalence rather than counted cases of invasive pneumococcal disease in the pediatric trial population. The Reddit discussion illustrates a communication gap, where the absence of a single effectiveness percentage for the new serotypes is read by some commenters as weak protection, even though bridging is the regulatory standard for such valency expansions.
还缺什么
The 25% effectiveness figure offered by the original poster has no identifiable source in the provided materials and remains 待确认. 据报道 [3], Pfizer posted a release dated May 20, 2026 titled "Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine," but the specific product, trial, or regulatory step referenced is 未披露 in the available materials. Real-world effectiveness data covering the 7 added serotypes in vaccinated children, along with any subsequent FDA label actions, would be the next data points to watch.
- 1.Individuals using assistive technology may not be able to fully · fda.gov 2026
- 2.A Phase Three Study of the Safety and Immunogenicity · pubmed.ncbi.nlm.nih.gov 2026
- 3.Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine · pfizer.com 2026
来源：社区讨论（Reddit） · reddit.com